At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
KTTA Pasithea Therapeutics Corp.
Pre-Market Trading 04-09 07:19:07 EDT
1.19
-0.02
-1.65%
| High1.23 | Low1.16 | Vol35.90K |
| Open1.21 | D1 Closing1.21 | Amplitude5.78% |
| Mkt Cap3.22M | Tradable Cap2.77M | Total Shares2.71M |
| T/O43.07K | T/O Rate1.54% | Tradable Shares2.33M |
| P/B-- | ROE-- | EPS0.00 |
| 52wk High-- | 52wk Low-- | P/E-- |
| Dividend-- | Div.Yield-- | ROA-- |
Loading ...
Pasithea Therapeutics to Present at the 2025 CAGLA NeauxCancer Conference
GlobeNewswire · 03-24
Psychedelic: Exclusive talk with biotech company Clearmind Medicine
TipRanks · 03-22
Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial
TipRanks · 03-14
Crude Oil Down 2%; ISM Services PMI Falls In January
Benzinga · 02-05
US Stocks Mixed; Walt Disney Posts Upbeat Earnings
Benzinga · 02-05
Pasithea Therapeutics Shares Rise After Positive Safety Review for Cancer Treatment
Dow Jones · 02-05
Top Premarket Gainers
MT Newswires Live · 02-05
Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation From Its Ongoing Phase 1 Clinical Trial of Pas-004 in Advanced Cancer
THOMSON REUTERS · 02-05
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
GlobeNewswire · 02-05
Pasithea Therapeutics opens three clinical trial sites in Eastern Europe
TIPRANKS · 01-14
Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4
THOMSON REUTERS · 01-14
Pasithea Therapeutics Corp - to Present Interim Safety and Pk Data in Q1 2025
THOMSON REUTERS · 01-14
Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4
GlobeNewswire · 01-14
BRIEF-Pasithea Therapeutics Entered Into Sales Agreement Relating To Sale Of Shares Of Common Stock Of Up To $2.1 Million From Time To Time
Reuters · 2024-11-26
BRIEF-Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation
Reuters · 2024-11-20
Pasithea Therapeutics announces SRC recommended proceeding to cohort 4
TIPRANKS · 2024-11-20
Pasithea Therapeutics Corp - to Proceed to Cohort 4, 15Mg Capsule for Pas-004
THOMSON REUTERS · 2024-11-20
Pasithea Therapeutics Corp - Src Recommends Escalation to 15Mg Dose Level
THOMSON REUTERS · 2024-11-20
Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation From Its Ongoing Phase 1 Clinical Trial of Pas-004 in Advanced Cancer
THOMSON REUTERS · 2024-11-20
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
GlobeNewswire · 2024-11-20
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
Introduction
Company Name.
Pasithea Therapeutics Corp.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Issue price:
--
Invest in Global Markets with Tiger Brokers!Open App